Elsevier
Journal of Thoracic Oncology
,  volume 19 ,  issue 10 ,  pages S281

P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma

A. Scherpereel 1
, 
D A Fennell 2
, 
N Fujimoto 3
, 
M.E. Marmarelis 4
, 
A Tsao 5
, 
J. Aerts 6
, 
X. Li 7
, 
T Dalvi 7
, 
H. Jiang 7
, 
L Krug 8
, 
M Zauderer 9, 10
1
 
2
 
3
 
Department of Medical Oncology, Okayama Rosai Hospital, Okayama/JP | 
4
 
5
 
6
 
7
 
AstraZeneca, Gaithersburg/MD/USA | 
8
 
9
 
10
 
Publication type: Journal Article
Publication date: 2024-10-15
Elsevier
scimago Q1
wos Q1
SJR: 7.948
CiteScore: 34.9
Impact factor: 20.8
ISSN: 15560864, 15561380
Found 

Top-30

Journals

1
Current Oncology
Current Oncology, 1, 50%
Current Oncology
1 publication, 50%
International Journal of Molecular Sciences
International Journal of Molecular Sciences, 1, 50%
International Journal of Molecular Sciences
1 publication, 50%
1

Publishers

1
2
MDPI
MDPI, 2, 100%
MDPI
2 publications, 100%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
2
Share
Cite this
GOST |
Cite this
GOST Copy
Scherpereel A. et al. P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma // Journal of Thoracic Oncology. 2024. Vol. 19. No. 10. p. S281.
GOST all authors (up to 50) Copy
Scherpereel A., Fennell D. A., Fujimoto N., Marmarelis M., Tsao A., Aerts J., Li X., Dalvi T., Jiang H., Krug L., Zauderer M. P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma // Journal of Thoracic Oncology. 2024. Vol. 19. No. 10. p. S281.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.jtho.2024.09.506
UR - https://linkinghub.elsevier.com/retrieve/pii/S1556086424013807
TI - P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma
T2 - Journal of Thoracic Oncology
AU - Scherpereel, A.
AU - Fennell, D A
AU - Fujimoto, N
AU - Marmarelis, M.E.
AU - Tsao, A
AU - Aerts, J.
AU - Li, X.
AU - Dalvi, T
AU - Jiang, H.
AU - Krug, L
AU - Zauderer, M
PY - 2024
DA - 2024/10/15
PB - Elsevier
SP - S281
IS - 10
VL - 19
SN - 1556-0864
SN - 1556-1380
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Scherpereel,
author = {A. Scherpereel and D A Fennell and N Fujimoto and M.E. Marmarelis and A Tsao and J. Aerts and X. Li and T Dalvi and H. Jiang and L Krug and M Zauderer},
title = {P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma},
journal = {Journal of Thoracic Oncology},
year = {2024},
volume = {19},
publisher = {Elsevier},
month = {oct},
url = {https://linkinghub.elsevier.com/retrieve/pii/S1556086424013807},
number = {10},
pages = {S281},
doi = {10.1016/j.jtho.2024.09.506}
}
MLA
Cite this
MLA Copy
Scherpereel, A., et al. “P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma.” Journal of Thoracic Oncology, vol. 19, no. 10, Oct. 2024, p. S281. https://linkinghub.elsevier.com/retrieve/pii/S1556086424013807.